ALNY vs AVDL · P/E 76, rev $1.29B vs rev $169.1M
Alnylam Pharmaceuticals Inc (ALNY) versus Avadel Pharmaceuticals PLC (AVDL) — a side-by-side from cached financials, not a winner call.
Alnylam Pharmaceuticals Inc (ALNY) is a biotechnology company listed on US.
Avadel Pharmaceuticals PLC (AVDL) is a drug manufacturers - specialty & generic company listed on US.
Latest reported ALNY revenue for 2026-06-30 was $1.29B. Net income was $164.5M. Revenue was up 3.4% from 2025-09-30 to 2026-06-30. ALNY currently screens at market cap $40.46B and trailing P/E 76.3.
Latest reported AVDL revenue for 2024-12-31 was $169.1M. Net income was -$48.8M. Revenue was up 504.8% from 2023-12-31 to 2024-12-31. AVDL currently screens at market cap $968.5M.
ALNY currently screens at market cap $40.46B and trailing P/E 76.3. AVDL currently screens at market cap $968.5M.
Not investment advice. Open the ALNY and AVDL stock pages for the full models.
Not investment advice.